What should I do if I become resistant to Sonidegib?

Sonidegib has been approved by the FDA for the treatment of basal cell carcinoma. It is a SMO antagonist and a natural alkaloid called cyclopamine. The first group of inhibitors targeting the Hh pathway are smooth (SMO) antagonists, approved for the first time in the treatment of basal cell carcinoma. However, as in other targeted cancer therapies, resistance emerges and reduces the efficacy of these inhibitors.

To avoid drug resistance, it is crucial to understand the mechanisms of primary and acquired resistance of tumors to conventionalSMO inhibitor treatments. Several strategies have been proposed to overcome drug resistance in cancer therapy. The first approach is to develop new and potent second-generation SMO inhibitors that maintain their anticancer activity even in the presence of resistance mutations. Furthermore, targeting downstream components of SMO in the Hh pathway or signaling molecules involved in unconventional pathways may be a promising alternative challenge to overcome resistance to SMO inhibitors. Genetic prescreening may provide an opportunity to avoid primary resistance to SMO inhibitors.

Solidagen is a new type of drug for treating diseases. Although the original drug Solidagen has been marketed in China, it has not yet entered the scope of medical insurance, and its price has not yet been determined. The Original drug Solidaget listed overseas, European version specificationsThe price per box of 200mg*30 tablets is around RMB 46,000 (the price may fluctuate due to the exchange rate), which is relatively expensive. The ingredients of the two drugs are basically the same. There is currently no generic version of Solidaget produced and marketed. For specific prices and drug information, please consult Yaodei Medical Consultants.